Impax Labs (IPXL), Zogenix (ZGNX) Rise as FDA Won't Block Generic Opana (ENDP)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Gabelli Sees Buying Opp in Endo Health (ENDP)
May 14, 2013 11:39 AM EDTShares of Endo Health (NASDAQ: ENDP) declined recently on news the FDA rejected Endo's Opana claims, allowing generic to remain on market. In the view of analysts at Gabelli, the sell-off is buying opportunity.
"While the FDA's decision is clearly a negative for Endo, we... More
CRT Capital Downgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Fairly Valued
May 13, 2013 8:50 AM EDTCRT Capital downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Buy to Fairly Valued.
For an analyst ratings summary and ratings history on Endo Pharmaceuticals Holdings Inc click here. For more ratings news on Endo... More
William Blair Downgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Market Perform
May 13, 2013 8:49 AM EDTWilliam Blair downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Outperform to Market Perform with a price target of $36.00 (from $43.00).
For an analyst ratings summary and ratings history on Endo Pharmaceuticals Holdings Inc... More
Jefferies Cuts Numbers on Endo Pharmaceuticals (ENDP) After 'Irrational' FDA Decision
May 13, 2013 7:25 AM EDTJefferies lowered its price target and estimates on Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) after the FDA denied a petition to block generic Opana.
Analyst Corey Davis, Ph.D. comments, "We were wrong, FDA acted irrationally inconsistent, in our view, and will... More
Lazard Capital Downgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Sell
May 13, 2013 7:09 AM EDTLazard Capital downgraded Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) from Neutral to Sell.
For an analyst ratings summary and ratings history on Endo Pharmaceuticals Holdings Inc click here. For more ratings news on Endo... More
